MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: Depemokimab

Depemokimab

Latest news

Tag

Allergy & Immunology

Twice-Yearly Depemokimab Maintained Asthma Control After Switching From Mepolizumab or Benralizumab, but Did Not Meet Formal Noninferiority for Exacerbations

In the phase 3A NIMBLE trial, switching biologic-responsive severe asthma patients to twice-yearly depemokimab preserved overall control and showed comparable safety, but formal noninferiority versus continued mepolizumab or benralizumab fo

May 29, 2026
Allergy & Immunology

FDA Approve Twice-Yearly Depemokimab for Severe Eosinophilic Asthma Management

The FDA has approved depemokimab (Exdensur), the first long-acting biologic for severe eosinophilic asthma. Requiring only two doses per year, it significantly reduces exacerbations and hospitalizations, offering a transformative shift in t

Dec 20, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story